公开(公告)号：US11207336B2

公开(公告)日：2021-12-28

申请号：US16846983

申请日：2020-04-13

Applicant: CMPD Licensing, LLC

Inventor： Jay Richard Ray, II

IPC: A61K31/7036 ,  A61K9/00 ,  A61K9/08 ,  A61K31/5383 ,  A61K9/06 ,  A61K9/48 ,  A61K9/14 ,  A61K31/351 ,  A61K31/7056 ,  A61K38/12 ,  A61K31/496 ,  A61K31/506 ,  A61K31/431 ,  A61K31/7048 ,  A61K31/65 ,  A61K45/06

Abstract: The present application relates to compounded compositions, methods of making compounded compositions, and methods of using compounded compositions. For example, disclosed herein are compounded compositions and methods of making compounded compositions comprising one or more anti-infective agents such as streptomycin and one or more of colistimethate, clindamycin, mupirocin, or levofloxacin.

公开(公告)号：US11198689B2

公开(公告)日：2021-12-14

申请号：US16551393

申请日：2019-08-26

Applicant: Rigel Pharmaceuticals, Inc.

Inventor： Hui Li ,  Sambaiah Thota ,  David Carroll ,  Ankush Argade ,  Kin Tso ,  Arvinder Sran ,  Jeffrey Clough ,  Holger Keim ,  Somasekhar Bhamidipati ,  Vanessa Taylor ,  Robin Cooper ,  Rajinder Singh ,  Brian Wong

IPC: C07D403/04 ,  C07D413/12 ,  C07D239/42 ,  C07D401/12 ,  C07D403/12 ,  C07D413/14 ,  C07D239/48 ,  A61K31/343 ,  A61K31/436 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/541 ,  A61K31/695 ,  A61K38/13 ,  A61K39/395 ,  C07D498/04 ,  C07F7/10 ,  A61K45/06 ,  C07D401/14 ,  C07D417/12 ,  C07F7/08 ,  C07D285/22

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

公开(公告)号：US20210369726A1

公开(公告)日：2021-12-02

申请号：US17098272

申请日：2020-11-13

Applicant: Hiroaki Serizawa

Inventor： Hiroaki Serizawa

IPC: A61K31/5383 ,  A61K31/496 ,  A61K9/00 ,  A61K9/08 ,  A61K31/435 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/26

Abstract: Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations.

公开(公告)号：US20210353609A1

公开(公告)日：2021-11-18

申请号：US17306928

申请日：2021-05-03

Applicant: CENTRE FOR DIGESTIVE DISEASES

Inventor： Thomas Julius BORODY

IPC: A61K31/4439 ,  A61P31/04 ,  A61K31/4178 ,  A61K31/424 ,  A61K31/426 ,  A61K31/43 ,  A61K31/438 ,  A61K31/5383 ,  A61K31/65 ,  A61K33/245

Abstract: Provided are methods for treating, ameliorating, reversing and/or preventing a Helicobacter pylori (H. pylori) infection in an individual in need thereof, comprising: administering to the individual in need thereof a therapeutic combination comprising: (a) a composition comprising or consisting of: vonoprazan or a vonoprazan fumarate, or a 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine monofumarate, or a 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methyl-methanamine fumarate), optionally TAKECAB™; and (b) an antimicrobial or antibiotic drug or composition.

公开(公告)号：US20210346364A1

公开(公告)日：2021-11-11

申请号：US17385258

申请日：2021-07-26

Applicant: MERCK SHARP & DOHME CORP.

Inventor： John P. CALDWELL ,  Reynalda DE JESUS ,  Fa-Xiang DING ,  Charles J. GIll ,  Ginny Dai HO ,  Sookhee N. HA ,  Sandra J. KOSEOGLU ,  Marc A. LABROLI ,  Sang Ho LEE ,  Christina MADSEN-DUGGAN ,  Mihir MANDAL ,  Terry ROEMER ,  Jing SU ,  Christopher Michael TAN ,  Zheng TAN ,  Haifeng TANG ,  Hao WANG ,  Christine YANG ,  Shu-Wei YANG

IPC: A61K31/4439 ,  A61P31/04 ,  A61K31/407 ,  A61K31/421 ,  A61K31/422 ,  A61K31/427 ,  A61K31/431 ,  A61K31/4375 ,  A61K31/438 ,  A61K31/4709 ,  A61K31/5377 ,  A61K31/5383 ,  C07D263/26 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04

Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a β-lactam antibiotic.

公开(公告)号：US20210267953A1

公开(公告)日：2021-09-02

申请号：US17262278

申请日：2019-07-24

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Ranjit DESAI ,  Vrajesh PANDYA ,  Mehul PUJARA ,  Anil ARGADE ,  Jignesh JOSHI ,  Anshul SATYANAND

IPC: A61K31/438 ,  A61P31/04 ,  C07D495/10 ,  C07D491/107 ,  C07D413/14 ,  A61K31/454 ,  A61K31/496 ,  A61K31/7036 ,  A61K31/5383 ,  A61K31/606 ,  A61K31/4409 ,  A61K31/133 ,  A61K31/4965

Abstract: Present invention relates to novel compound of formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection.

公开(公告)号：US11098051B2

公开(公告)日：2021-08-24

申请号：US16328616

申请日：2017-08-25

Applicant: Novartis AG

Inventor： Rama Jain ,  Dennis Christofer Koester ,  James R. Manning ,  Vanessa Marx ,  Daniel Poon ,  James Clifford Sutton ,  Benjamin Robert Taft ,  Lifeng Wan ,  Aregahegn Yifru ,  Qian Zhao

IPC: C07D487/14 ,  C07D471/14 ,  C07D498/14 ,  A61P31/16 ,  A61K31/16 ,  A61K31/5025 ,  A61K31/53 ,  A61K31/5365 ,  A61K31/5383 ,  A61K31/551

Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.

公开(公告)号：US11096889B2

公开(公告)日：2021-08-24

申请号：US16717004

申请日：2019-12-17

Applicant: WAKAMOTO PHARMACEUTICAL CO., LTD.

Inventor： Takeshi Yamamura ,  Ayaka Yamamuro ,  Emi Izukura ,  Moto Kimura ,  Tomohiro Otsuka

IPC: A61K9/00 ,  A61K31/194 ,  A61P27/02 ,  A61K47/32 ,  A61K47/10 ,  A61K47/38 ,  A61K31/5383 ,  A61K47/12 ,  A61K9/06 ,  A61P27/04

Abstract: The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.

公开(公告)号：US11085022B2

公开(公告)日：2021-08-10

申请号：US15512726

申请日：2014-11-27

Applicant: CHINA PHARMACEUTICAL UNIVERSITY

Inventor： Can Zhang ,  Jingwei Xue ,  Zekai Zhao ,  Lei Zhang ,  Yajing Wen

IPC: C12N5/0787 ,  A61K38/19 ,  A61K38/22 ,  G01N33/50 ,  A61K31/337 ,  A61K31/5383 ,  A61K31/7105 ,  A61K9/50 ,  A61K9/127 ,  A61K45/06 ,  A61K31/192 ,  A61K31/711 ,  C07K14/715 ,  B82Y5/00

Abstract: Disclosed are an inflammation-targeted neutrophil granulocyte drug delivery system and use thereof, wherein the drug delivery system includes neutrophil granulocytes and a therapeutic substance or a detectable substance loaded into the neutrophil granulocytes or onto the surface of the neutrophil granulocytes in a direct or indirect way. By using the neutrophil granulocytes as a carrier of a drug, the drug is actively targeted to an inflammatory site, thereby increasing the drug concentration at the inflammatory site. Under the stimulation of cytokines, the neutrophil granulocytes arriving at the inflammatory site are abnormally activated, disintegrate rapidly, and die in the way of “Neutrophil extracellular traps (NETs)”. This helps to rapidly release the loaded drug to the targeted site, so as to improve the therapeutic effect and reduce the toxic and side effects.

公开(公告)号：US20210228590A1

公开(公告)日：2021-07-29

申请号：US17204246

申请日：2021-03-17

Applicant: SHIONOGI & CO., LTD.

Inventor： Takao SHISHIDO ,  Keita FUKAO ,  Takeshi NOSHI ,  Yoshinori ANDO ,  Takahiro NODA

IPC: A61K31/5383 ,  A61P31/16 ,  A61K9/00 ,  A61K9/28 ,  A61K9/48 ,  A61K9/06 ,  A61K31/245 ,  A61K45/06 ,  A61K9/70

Abstract: A method for treating influenza is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having influenza, where the compound is administered initially at least about 48 hours after an onset of influenza. Generally, the effective amount is sufficient to alleviate a symptom of influenza in the subject as compared to a symptom that the subject has when the compound is first administered to the subject.